Literature DB >> 17537768

New recommendations for duration of respiratory isolation based on time to detect Mycobacterium tuberculosis in liquid culture.

S R Ritchie1, A C Harrison, R H Vaughan, L Calder, A J Morris.   

Abstract

It was hypothesised that the time to detect Mycobacterium tuberculosis in liquid culture of sputum from patients with pulmonary tuberculosis may be a better indicator for the duration of respiratory isolation than sputum smear status. Pre-treatment and during-treatment sputum acid-fast bacilli (AFB) smear and culture results were reviewed in 284 patients with pulmonary tuberculosis. The time to detect M. tuberculosis in liquid culture (TTD-TB) was the number of days from inoculation of the Mycobacterial Growth Indicator Tube to culture detection and visualisation of AFB. The median (interquartile range) TTD-TB for smear group 0 (no bacilli seen) was 14 (12-20) days. This value was used as the standard at which release from isolation could be permitted. In smear group 4 (>9 AFB per high-power field (hpf) in sputum specimens before treatment) patients, the TTD-TB exceeded 14 days after a median of 25 days of treatment. The current authors recommend that patients in smear groups 1 and 2 (1-9 AFB per 100 hpf and 1-9 AFB per 10 hpf in sputum specimens before treatment, respectively) receive treatment in respiratory isolation for 7 days, provided the risk of drug resistance is low. Smear group 3 (1-9 AFB per hpf) and 4 patients should receive treatment in respiratory isolation for 14 and 25 days, respectively. These criteria would have reduced the duration of respiratory isolation by 1,516 days in the 143 study participants with sputum smear-positive pulmonary tuberculosis. Provided clinical and radiographical criteria are satisfactory, use of the time to detect Mycobacterium tuberculosis in liquid culture could enable the duration of respiratory isolation to be predicted from the pre-treatment sputum smear grade. The recommendations enable isolation to end well before sputum becomes smear negative, with considerable benefits to patients and healthcare providers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537768     DOI: 10.1183/09031936.00131406

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

Review 1.  Value of Xpert MTB/RIF Using Bronchoalveolar Lavage Fluid for the Diagnosis of Pulmonary Tuberculosis: a Systematic Review and Meta-analysis.

Authors:  Hong-Chao Liu; Yu-Lu Gao; Dan-Feng Li; Xi-Yi Zhao; Yuan-Qing Pan; Chang-Tai Zhu
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

2.  Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis.

Authors:  Luciene C Scherer; Rosa D Sperhacke; Antonio Ruffino-Netto; Maria Lr Rossetti; Claudia Vater; Paul Klatser; Afrânio L Kritski
Journal:  BMC Infect Dis       Date:  2009-12-31       Impact factor: 3.090

3.  Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden.

Authors:  Richard N van Zyl-Smit; Anke Binder; Richard Meldau; Hridesh Mishra; Patricia L Semple; Grant Theron; Jonathan Peter; Andrew Whitelaw; Suren K Sharma; Robin Warren; Eric D Bateman; Keertan Dheda
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

4.  Smear plus Detect-TB for a sensitive diagnosis of pulmonary tuberculosis: a cost-effectiveness analysis in an incarcerated population.

Authors:  Karen Barros Schmid; Luciene Scherer; Regina Bones Barcellos; Daniele Kuhleis; Isaías Valente Prestes; Ricardo Ewbank Steffen; Elis Regina Dalla Costa; Maria Lucia Rosa Rossetti
Journal:  BMC Infect Dis       Date:  2014-12-16       Impact factor: 3.090

5.  The effectiveness of real-time PCR assay, compared with microbiologic results for the diagnosis of pulmonary tuberculosis.

Authors:  Seo Woo Kim; Sae In Kim; Seok Jeong Lee; Jin Hwa Lee; Yun Ju Ryu; Sung Shine Shim; Yookyoung Kim; Mi Ae Lee; Jung Hyun Chang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-01-29

6.  Clinical diagnostic value of simultaneous amplification and testing for the diagnosis of sputum-scarce pulmonary tuberculosis.

Authors:  Liping Yan; Qing Zhang; Heping Xiao
Journal:  BMC Infect Dis       Date:  2017-08-05       Impact factor: 3.090

7.  Culture conversion rate at 2 months of treatment according to diagnostic methods among patients with culture-positive pulmonary tuberculosis.

Authors:  Ha Youn Lee; Kyoung Ok Chae; Chang Hoon Lee; Sun Mi Choi; Jinwoo Lee; Young Sik Park; Sang-Min Lee; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Jae-Joon Yim
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

Review 8.  Indications to Hospital Admission and Isolation of Children With Possible or Defined Tuberculosis: Systematic Review and Proposed Recommendations for Pediatric Patients Living in Developed Countries. [Corrected].

Authors:  Andrea Lo Vecchio; Marialuisa Bocchino; Laura Lancella; Clara Gabiano; Silvia Garazzino; Riccardo Scotto; Irene Raffaldi; Luca Rosario Assante; Alberto Villani; Susanna Esposito; Alfredo Guarino
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

9.  A Large Cohort Study on the Clinical Value of Simultaneous Amplification and Testing for the Diagnosis of Pulmonary Tuberculosis.

Authors:  Liping Yan; Shenjie Tang; Yan Yang; Xiang Shi; Yanping Ge; Wenwen Sun; Yidian Liu; Xiaohui Hao; Xuwei Gui; Hongyun Yin; Ya He; Qing Zhang
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

10.  Using simultaneous amplification and testing method for evaluating the treatment outcome of pulmonary tuberculosis.

Authors:  Liping Yan; Heping Xiao; Qing Zhang
Journal:  BMC Infect Dis       Date:  2018-10-11       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.